Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.
2.

Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans.

Herman BD, Fleishaker JC, Brown MT.

Clin Pharmacol Ther. 1999 Oct;66(4):374-9.

PMID:
10546921
3.

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic.

DeVane CL, Nemeroff CB.

Clin Pharmacokinet. 2001;40(7):509-22. Review.

PMID:
11510628
4.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
5.

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor.

Dostert P, Benedetti MS, Poggesi I.

Eur Neuropsychopharmacol. 1997 Apr;7 Suppl 1:S23-35; discussion S71-3. Review.

PMID:
9169308
6.

Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics.

Fleishaker JC, Mucci M, Pellizzoni C, Poggesi I.

Biopharm Drug Dispos. 1999 Jan;20(1):53-7.

PMID:
10086838
7.

Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.

Taylor TJ, Diringer K, Russell T, Venkatakrishnan K, Wilner K, Crownover PH, Benincosa LJ, Gibbs MA.

Clin Pharmacokinet. 2006;45(10):989-1001.

PMID:
16984212
8.

Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.

Kuhn UD, Kirsch M, Merkel U, Eberhardt AM, Wenda B, Maurer I, Härtter S, Hiemke C, Volz HP, Balogh A.

Int J Clin Pharmacol Ther. 2007 Jan;45(1):36-46.

PMID:
17256449
9.

Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine.

McEnroe JD, Fleishaker JC.

Clin Pharmacokinet. 2005;44(3):237-46. Review.

PMID:
15762767
10.

Pharmacokinetics of reboxetine enantiomers in the dog.

Frigerio E, Benecchi A, Brianceschi G, Pellizzoni C, Poggesi I, Strolin Benedetti M, Dostert P.

Chirality. 1997;9(3):303-6.

PMID:
9176997
11.

Clinical pharmacokinetics of mizolastine.

Lebrun-Vignes B, Diquet B, Chosidow O.

Clin Pharmacokinet. 2001;40(7):501-7. Review.

PMID:
11510627
12.
13.

Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression.

Scates AC, Doraiswamy PM.

Ann Pharmacother. 2000 Nov;34(11):1302-12. Review.

PMID:
11098346
14.
15.

Clinical pharmacokinetics of mirtazapine.

Timmer CJ, Sitsen JM, Delbressine LP.

Clin Pharmacokinet. 2000 Jun;38(6):461-74. Review.

PMID:
10885584
16.

Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers.

Markowitz JS, Donovan JL, Devane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD.

Clin Pharmacol Ther. 2003 Dec;74(6):536-42.

PMID:
14663456
17.

Hemodynamic effects of reboxetine in healthy male volunteers.

Denolle T, Pellizzoni C, Jannuzzo MG, Poggesi I.

Clin Pharmacol Ther. 1999 Sep;66(3):282-7.

PMID:
10511064
18.

Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.

Bramer SL, Suri A.

Clin Pharmacokinet. 1999;37 Suppl 2:41-51.

PMID:
10702886
19.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
20.

The clinical pharmacokinetics of escitalopram.

Rao N.

Clin Pharmacokinet. 2007;46(4):281-90. Review.

PMID:
17375980

Supplemental Content

Support Center